Article
Pharmacology & Pharmacy
Nikki de Rouw, Hieronymus J. Derijks, Luuk B. Hilbrands, Rene J. Boosman, Berber Piet, Stijn L. W. Koolen, Jacobus A. Burgers, Anne-Marie C. Dingemans, Michel M. van den Heuvel, Lizza E. L. Hendriks, Joachim G. J. V. Aerts, Sander Croes, Ron H. J. Mathijssen, Alwin D. R. Huitema, David M. Burger, Bonne Biesma, Rob ter Heine
Summary: The study found that dose adjustments of pemetrexed are not required during hyperhydration with cisplatin as hyperhydration did not significantly influence the clearance or volume of distribution of pemetrexed.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Hematology
Julie Kanter, R. Clark Brown, Cynthia Norris, Santosh M. Nair, Abdullah Kutlar, Deepa Manwani, Nirmish Shah, Chiaki Tanaka, Shankaranand Bodla, Gessami Sanchez-Olle, Urs Albers, Darla Liles
Summary: This study analyzed the pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease. The results demonstrated the sustained efficacy and long-term safety of the drug in treating sickle cell disease.
Article
Pharmacology & Pharmacy
Peng Cao, Wei Guo, Jun Wang, Sanlan Wu, Yifei Huang, Yang Wang, Yani Liu, Yu Zhang
Summary: The purpose of this study was to identify physiological and genetic factors that contribute to variability in pemetrexed (PEM) exposure and optimize dosing regimens for Chinese non-small cell lung carcinoma patients. The study found that body surface area-based dosing method was not suitable to achieve target exposure in Chinese NSCLC patients, and a renal function-based dosing strategy is recommended.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Lea Darnaud, Benoit Blanchet, Jerome Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka
Summary: This study investigated the relationship between dose-limiting toxicity (ANC) and efficacy (PFS) in patients with metastatic breast cancer receiving palbociclib. The results showed that palbociclib-induced neutropenia had concentration-dependent and non-cumulative properties, and could be reversed after treatment withdrawal. Higher exposure to palbociclib was associated with a trend towards better PFS, particularly in older patients. This study provides support for clinicians to optimize treatment management through patient-individualized strategies.
Article
Pharmacology & Pharmacy
Max Tsai, Emel Serap Monkul Nery, Lisa Kerr, Rashna Khanna, Mika Komori, Ellen B. Dennehy, Darren Wilbraham, Paul Winner
Summary: The study evaluated the pharmacokinetics, safety, and tolerability of lasmiditan in pediatric migraine patients aged 6 to <18 years, showing similar exposure to the drug between different weight cohorts but differences in certain pharmacokinetic parameters. Adverse events were mild and comparable to adult studies, supporting further investigation of lasmiditan as a potential treatment in pediatric patients with migraine.
CLINICAL PHARMACOKINETICS
(2021)
Article
Multidisciplinary Sciences
Isabelle H. S. Kuan, Luke C. Wilson, Jed C. Leishman, Samuel Cosgrove, Robert J. Walker, Tracey L. Putt, John B. W. Schollum, Daniel F. B. Wright
Summary: Our study developed a dosing strategy for metformin based on kidney function to optimize efficacy and safety. By analyzing data from two studies and using simulations from a pharmacokinetic model, we found a strong relationship between metformin clearance and estimated kidney function. The probability of exceeding safety targets for plasma metformin concentration was generally low, supporting cautious use of metformin at appropriate doses in patients with impaired kidney function.
Article
Dermatology
Madison Grinnell, Kyla N. Price, Amit Shah, Daniel C. Butler
Summary: This review highlights the lack of dedicated geriatrics curriculum in residency training programs for dermatologists, leading to their limited knowledge on age-associated adverse effects of common dermatologic medications. It provides a practical guide and clinical safety pearls for the use of antihistamines in older adults, addressing the risks, anticholinergic burden, polypharmacy, preexisting medical conditions, and safe alternatives.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Clinical Neurology
Dong Won Kwack, Dong Wook Kim
Summary: This study explores the potential efficacy and safety of ESL oral loading in patients with epilepsy. Results show that most patients achieved therapeutic levels within 12 hours without exceeding the supratherapeutic level throughout the study. Reported adverse effects include gaze-evoked nystagmus and rash, but no serious adverse events leading to drug discontinuation occurred.
Article
Oncology
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Summary: The presence of non-evacuated third-space fluid in patients with advanced non-squamous NSCLC increases the risk of hematological toxicity when receiving Pemetrexed and platinum chemotherapy. Evacuation of third-space fluid in these patients can mitigate these adverse effects.
Article
Multidisciplinary Sciences
Hyun-Jung Lee, Hyung-Kwan Kim, Bong-Seong Kim, Kyung-Do Han, Chan Soon Park, Tae-Min Rhee, Jun-Bean Park, Heesun Lee, Yong-Jin Kim
Summary: Anti-tuberculosis treatment can interfere with effective anticoagulation. This study investigated the safety and effectiveness of using non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients on anti-tuberculosis treatment. The results showed that NOACs were associated with a lower risk of ischemic stroke compared to warfarin, while there was no significant difference in the risk of major bleeding or death.
SCIENTIFIC REPORTS
(2023)
Article
Rheumatology
Yen Lin Chia, Jianchun Zhang, Raj Tummala, Tomas Rouse, Richard A. Furie, Eric F. Morand
Summary: The study aimed to characterize the relationship between anifrolumab pharmacokinetics and efficacy, safety in patients with SLE. Results showed that higher anifrolumab serum concentration predicted greater efficacy, with consistent positive benefit favoring anifrolumab 300 mg over placebo in the trials.
Article
Microbiology
D. Busse, P. Simon, D. Petroff, N. El-Najjar, L. Schmitt, D. Bindellini, A. Dietrich, M. Zeitlinger, W. Huisinga, R. Michelet, H. Wrigge, C. Kloft
Summary: The objectives of this study were to identify the appropriate body size descriptor for fosfomycin dose adjustments and assess the adequacy of the currently employed dosing regimens in both obese and nonobese patients. The study showed that dosing should be guided by renal function rather than obesity status.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Endocrinology & Metabolism
Wonjung Shin, Marcus Hompesch, JinHee Byeon, Seohyun Kang, Jaehyuk Choi, Seungjae Baek
Summary: This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of a novel long-acting glucagon analogue HM15136 in overweight/obese patients with co-morbidities, with and without type 2 diabetes (T2D). The results showed that HM15136 had good safety and tolerability in patients with dyslipidaemia and/or hypertension, but its use in patients with T2D may cause hyperglycaemia.
DIABETES OBESITY & METABOLISM
(2023)
Article
Oncology
Xu Liang, Junli Xue, Xiaoxiao Ge, Jin Li, Huiping Li, Liqiong Xue, Lijun Di, Wenbo Tang, Guohong Song, Qun Li, Hanfang Jiang, Wei Zhao, Fengjuan Lin, Bin Shao, Xiugao Yang, Zhufeng Wu, Tianyi Zhang, Chenchen Wang, Ye Guo
Summary: Bone metastases are common complications of solid tumors. This study found that JMT103 is effective in treating bone metastases from solid tumors and is well tolerated by patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Mehmet Akce, Anthony El-Khoueiry, Sarina A. Piha-Paul, Emeline Bacque, Peng Pan, Zhi-Yi Zhang, Reginald Ewesuedo, Divya Gupta, Yongqiang Tang, Ashley Milton, Stefan Zajic, Patricia L. Judson, Cindy L. O'Bryant
Summary: This study aimed to characterize the pharmacokinetics and safety of niraparib in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). The results showed that MHI patients had increased plasma exposure to niraparib compared to NHF patients, but this did not affect tolerability. Adjusting the starting dose of niraparib from 300 mg to 200 mg QD in MHI patients is recommended based on these findings. Safety profiles were consistent across both patient groups.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)